Abstract:

Objective To evaluate thymidine kinase 1（TK1） and S-phase fraction（SPF） in peripheral blood for the diagnosis,treatment monitoring and prognosis of acute myeloid leukemia（AML）. Methods A total of 58 patients with AML were enrolled,and 6 patients with benign proliferative disease in hematological system and 20 healthy subjects were enrolled as well. TK1 levels were determined by dot-blot enhanced chemiluminescence,and SPF were calculated by flow cytometry. After a standard inductive treatment,the levels of TK1 and SPF were compared in remission group（39 cases,including 11 cases of complete remission and 28 cases of partial remission） and non-remission group（19 cases） with those before treatment. The levels of TK1 and SPF were determined at the time points of a week and a month after treatment. Results The levels of TK1 [（2.43±1.02）pmol/L] and SPF[（4.62±2.33）%] in AML group before treatment were higher than those in benign proliferative disease group [（1.12±0.41）pmol/L and（2.62±1.05）%] and healthy control group[（0.39±0.15）pmol/L and（2.21±0.96）%]（P<0.05）. The levels of TK1 [（0.78±0.44） pmol/L] and SPF [（1.89±1.23）%] decreased in complete remission group compared with those before treatment and in non-remission group [（4.26±0.46）pmol/L and（5.58±3.12）%]（P<0.05）. After a standard inductive treatment for a month,the levels of TK1 [（1.97±0.89）pmol/L] and SPF [（2.89±1.03）%] were lower than those before treatment（P<0.05）. Conclusions The combined determination of TK1 and SPF is accurate for the proliferation status of AML and can indicate treatment and prognosis status of AML.

Key words: Thymidine kinase 1, S-phase fraction, Acute myeloid leukemia